Whether Avatrombopag has been included in medical insurance and reimbursement policy

Avatrombopag is an oral thrombopoietic drug that is mainly used to treat patients with chronic liver disease due to thrombocytopenia and to increase platelets before surgery or invasive procedures. The drug stimulates platelet production, thereby reducing the risk of preoperative bleeding and ensuring the safety of clinical operations.

In the Chinese market, avatrombopag has been launched and included in medical insurance, and is available in two specifications: 20mg10 tablets and 20mg15 tablets. The latest price of 20mg10 tablets is more than 5,000 yuan, and the price of 20mg15 tablets is around 7,000 to 8,000 yuan. The actual payment amount after specific medical insurance reimbursement will vary according to different regions and hospital policies. Patients should consult the local hospital pharmacy before taking medication to ensure that the cost of medication is controllable.

In foreign markets, avatrombopag also has a variety of options, including the officially launched Laotian version and Bangladeshi version of generic drugs. The price of these generic drugs is only about a few hundred yuan, and they are basically the same as the original drugs in terms of composition and efficacy. They provide a feasible alternative for patients with limited economic conditions, especially suitable for long-term or repeated treatments.

Overall, the inclusion of avatrombopag in domestic medical insurance has reduced medication costs for patients while ensuring clinical accessibility. When selecting drug specifications and purchase channels, patients should make scientific decisions based on their own treatment needs, economic conditions and the guidance of doctors to ensure maximum treatment safety and efficacy.

Reference materials:https://www.drugs.com/